References:
1.
Sung
H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and
Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin.
2021 2021-05-01;71(3):209-49.
2.
Koulouris
A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M.
Hepatocellular Carcinoma: An Overview of the Changing Landscape of
Treatment Options. J Hepatocell Carcinoma. 2021 2021-01-20;8:387-401.
3.
Rumgay
H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global,
regional and national burden of primary liver cancer by subtype. EUR J
CANCER. 2022 2022-01-01;161:108-18.
4.
Kulik
L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma.
GASTROENTEROLOGY. 2019 2019-01-01;156(2):477-91.
5.
Yang
JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view
of hepatocellular carcinoma: trends, risk, prevention and management.
Nat Rev Gastroenterol Hepatol. 2019 2019-10-01;16(10):589-604.
6. Fan
Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma:
Current Updates and Outlook. J Hepatocell Carcinoma. 2022
2022-01-20;9:233-63.
7.
Falette
PM, Pellat A, Assaf A, Ginestet C, Brezault C, Dhooge M, et al.
Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated
Review. Cancers (Basel). 2022 2022-05-10;14(10).
8. Qin
S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis
receptor tyrosine kinase inhibitors in cancer therapy. J HEMATOL ONCOL.
2019 2019-03-12;12(1):27.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008
2008-07-24;359(4):378-90.
10. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy
and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised, double-blind,
placebo-controlled trial. LANCET ONCOL. 2009 2009-01-01;10(1):25-34.
11. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et
al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor
that targets multiple receptor tyrosine kinases in preclinical human
thyroid cancer models. J Thyroid Res. 2014 2014-01-20;2014:638747.
12. Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y,
Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor
fibroblast growth factor signaling pathways in human hepatocellular
carcinoma models. Cancer Med. 2018 2018-06-01;7(6):2641-53.
13. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al.
Lenvatinib versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: a randomised phase 3
non-inferiority trial. LANCET. 2018 2018-03-24;391(10126):1163-73.
14.
Sherman
M. Regorafenib for treatment of hepatocellular carcinoma. HEPATOLOGY.
2018 2018-03-01;67(3):1162-5.
15. Galle PR, Dufour JF, Peck-Radosavljevic M, Trojan J, Vogel A.
Systemic therapy of advanced hepatocellular carcinoma. FUTURE ONCOL.
2021 2021-04-01;17(10):1237-51.
16. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al.
Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind,
placebo-controlled, phase 3 trial. LANCET. 2017
2017-01-07;389(10064):56-66.
17. Tumen D, Heumann P, Gulow K, Demirci CN, Cosma LS, Muller M, et al.
Pathogenesis and Current Treatment Strategies of Hepatocellular
Carcinoma. Biomedicines. 2022 2022-12-09;10(12).
18. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY,
et al. Cabozantinib in Patients with Advanced and Progressing
Hepatocellular Carcinoma. N Engl J Med. 2018 2018-07-05;379(1):54-63.
19.
Justice
CN, Derbala MH, Baich TM, Kempton AN, Guo AS, Ho TH, et al. The Impact
of Pazopanib on the Cardiovascular System. J Cardiovasc Pharmacol Ther.
2018 2018-09-01;23(5):387-98.
20.
Dobbin
S, Petrie MC, Myles RC, Touyz RM, Lang NN. Cardiotoxic effects of
angiogenesis inhibitors. Clin Sci (Lond). 2021 2021-01-15;135(1):71-100.
21.
Pinkhas
D, Ho T, Smith S. Assessment of pazopanib-related hypertension, cardiac
dysfunction and identification of clinical risk factors for their
development. Cardiooncology. 2017 2017-01-20;3.
22.
Fan Q,
Hu Y, Yang C, Zhao B. Myocarditis following the use of different immune
checkpoint inhibitor regimens: A real-world analysis of post-marketing
surveillance data. INT IMMUNOPHARMACOL. 2019 2019-11-01;76:105866.
23.
Sakaeda
T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of
the FDA Adverse Event Reporting System. INT J MED SCI. 2013
2013-01-20;10(7):796-803.
24.
Moslehi
JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J
Med. 2016 2016-10-13;375(15):1457-67.
25. Li
W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular
and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on
Kinase Inhibitors. J AM COLL CARDIOL. 2015 2015-09-08;66(10):1160-78.
26.
Rimassa
L, Danesi R, Pressiani T, Merle P. Management of adverse events
associated with tyrosine kinase inhibitors: Improving outcomes for
patients with hepatocellular carcinoma. CANCER TREAT REV. 2019
2019-07-01;77:20-8.
27.
Wirth
LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, et al.
Treatment-emergent hypertension and efficacy in the phase 3 Study of
(E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
CANCER-AM CANCER SOC. 2018 2018-06-01;124(11):2365-72.
28. Yuan X, Mitsis A, Nienaber CA. Current Understanding of Aortic
Dissection. Life (Basel). 2022 2022-10-14;12(10).
29.
Tsuchiya
A, Ogawa M, Watanabe Y, Kimura N, Hayashi K, Suda T, et al. Successful
treatment of aortic dissection during sorafenib therapy for
hepatocellular carcinoma. Clin Case Rep. 2018 2018-08-01;6(8):1643-4.
30.
Takada
M, Yasui T, Oka T, Shioyama W, Kuroda T, Nakai Y, et al. Aortic
Dissection and Cardiac Dysfunction Emerged Coincidentally During the
Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal
Cell Carcinoma. INT HEART J. 2018 2018-09-26;59(5):1174-9.
31.
Oshima
Y, Tanimoto T, Yuji K, Tojo A. Association Between Aortic Dissection and
Systemic Exposure of Vascular Endothelial Growth Factor Pathway
Inhibitors in the Japanese Adverse Drug Event Report Database.
CIRCULATION. 2017 2017-02-21;135(8):815-7.
32.
Zhou
Z, Cecchi AC, Prakash SK, Milewicz DM. Risk Factors for Thoracic Aortic
Dissection. Genes (Basel). 2022 2022-10-07;13(10).
33.
Dorks
M, Jobski K, Herget-Rosenthal S, Hoffmann F, Douros A. Tyrosine kinase
inhibitors targeting vascular endothelial growth factor and the risk of
aortic dissection-A pharmacovigilance analysis. Pharmacol Res Perspect.
2021 2021-02-01;9(1):e707.
34.
Hatem
R, Bebawi E, Schampaert E. Potential Sunitinib-Induced Coronary Artery
and Aortic Dissections. CAN J CARDIOL. 2017 2017-06-01;33(6):817-30.
35.
Niwa
N, Nishiyama T, Ozu C, Yagi Y, Saito S. Acute aortic dissection in a
patient with metastatic renal cell carcinoma treated with axitinib. ACTA
ONCOL. 2015 2015-04-01;54(4):561-2.
36.
Bonnet
C, Sibon I. Potential role of anti-VEGF targeted therapies in cervical
artery dissection: A case report. Rev Neurol (Paris). 2015
2015-09-01;171(8-9):677-9.
37. Bronte G, Bronte E, Novo G, Pernice G, Lo VF, Musso E, et al.
Conquests and perspectives of cardio-oncology in the field of tumor
angiogenesis-targeting tyrosine kinase inhibitor-based therapy. EXPERT
OPIN DRUG SAF. 2015 2015-02-01;14(2):253-67.
38.
Chintalgattu
V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, et al. Cardiomyocyte
PDGFR-beta signaling is an essential component of the mouse cardiac
response to load-induced stress. J CLIN INVEST. 2010
2010-02-01;120(2):472-84.
39.
Touyz
RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor
inhibitor therapy. NPJ Precis Oncol. 2018 2018-01-20;2:13.
40.
Scott
SS, Greenlee AN, Matzko A, Stein M, Naughton MT, Zaramo TZ, et al.
Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor
Cardiotoxicity. HEART FAIL CLIN. 2022 2022-07-01;18(3):425-42.
41.
Kivela
R, Hemanthakumar KA, Vaparanta K, Robciuc M, Izumiya Y, Kidoya H, et al.
Endothelial Cells Regulate Physiological Cardiomyocyte Growth via
VEGFR2-Mediated Paracrine Signaling. CIRCULATION. 2019
2019-05-28;139(22):2570-84.
42.
Takagi
K, Takai M, Kawata K, Horie K, Kikuchi M, Kato T, et al. [Three
Patients with Acute Myocardial Infarction Associated with Targeted
Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case
Report]. Hinyokika Kiyo. 2015 2015-09-01;61(9):347-51.
43.
Paschke
L, Lincke T, Muhlberg K, Lindner TH, Paschke R. Myocardial Infarction
after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with
Anti-VEGF Receptor Activity. Case Rep Endocrinol. 2019
2019-01-20;2019:7927450.
44.
Duran
JM, Makarewich CA, Trappanese D, Gross P, Husain S, Dunn J, et al.
Sorafenib cardiotoxicity increases mortality after myocardial
infarction. CIRC RES. 2014 2014-05-23;114(11):1700-12.
45.
Petrini
I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, et al.
Phase II trial of sorafenib in combination with 5-fluorouracil infusion
in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2012
2012-03-01;69(3):773-80.
46. Lu
Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, et al. Suppression
of phosphoinositide 3-kinase signaling and alteration of multiple ion
currents in drug-induced long QT syndrome. SCI TRANSL MED. 2012
2012-04-25;4(131):131r-150r.